Bertrand Dubois

8PUBLICATIONS
88CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCellular immunologyGene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jan 06, 2026
Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trial.

Isabelle Ray-Coquard, Marie-Christine Kaminsky-Forrett, Ryotaro Ohkuma

|Jun 25, 2025
Phase I First-in-Human Study of TRK-950, an IgG1 Antibody Specific to CAPRIN-1, in Patients with Advanced Solid Tumors.

Philippe A Cassier, Mitesh J Borad, Sunil Sharma

|May 16, 2025
Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial.

Laetitia Collet, Maude Ardin, David Venet

|Jan 08, 2025
The Spatial Organization of cDC1 with CD8+ T Cells is Critical for the Response to Immune Checkpoint Inhibitors in Patients with Melanoma.

Elisa Gobbini, Margaux Hubert, Anne-Claire Doffin

|Aug 21, 2024
KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer.

Sara Santagata, Anna Maria Trotta, Crescenzo D'Alterio

|Jan 24, 2024
The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.

Aurélien Voissière, Carlos Gomez-Roca, Sylvie Chabaud

Pageof 2

Frequent Collaborators

6 joint publications

Christophe Caux

4 joint publications

Justine Berthet

2 joint publications

Margaux Hubert

2 joint publications

Elisa Gobbini